ERBB2 and breast cancer: Foretinib induced caspase-dependent apoptosis in ovarian cancer and chronic myelogenous leukemia cell lines [10, 48], while lapatinib was particularly effective in breast cancer cell lines – triple-negative as well as HER2-positive [49, 50] - and gefitinib in non-small lung cancer cells with mutated EGFR [51].